Although the influenza 2009 H1N1 vaccine produced by Novartis, Fluvirin, was previously approved for use in the US, the clinical data supporting its safety and immunogenicity had not been released. The company has now issued a media release containing interim clinical data on the effects of the vaccine in humans. According to the company, testing …
Hosts: Vincent Racaniello and Jason Rodriguez On episode #50 of the podcast “This Week in Virology”, Vincent and Jason review influenza 2009 H1N1 vaccine trials and protection against the virus conferred by the 1976 swine flu vaccine, then move on to a virus called XMRV and its possible role in prostate cancer. [powerpress url=”http://traffic.libsyn.com/twiv/TWiV050.mp3″] Click …
There has been a great deal of discussion about the use of adjuvants to improve the immunogenicity of vaccines against the 2009 H1N1 pandemic influenza strain. What effect do these compounds have on the immune response? Adjuvants are compounds added to vaccines that stimulate the immune response. They are often used when the antigen is …
